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Abstract: The aim of this study was to determine the intensity of Hsp27 protein expression in fibrocystic breast
changes (FC) and invasive ductal breast carcinoma (IDC) and to examine its impact on patients’ clinico-patho-
logical characteristics and overall survival. Immunohistochemical reactions were conducted on archival samples
of 20 cases of FC and 101 cases of IDC treated in 1999–2002. Nuclear-cytoplasmic Hsp27 expression was ob-
served in 92 (92.1%) of the examined cases of IDC, and all the cases of FC. Significantly higher Hsp27 expres-
sion was observed in G2 (p < 0.01) and G3 cases (p < 0.0001) compared to FC. HER-2 positive cases had higher
Hsp27 expression (p = 0.0153), than HER-2 negative cases. Our research showed that Hsp27 could have an
impact on tumor malignancy. Moreover, a positive correlation between the expression of Hsp27 and HER-2
positive cases was demonstrated. (Folia Histochemica et Cytobiologica 2012, Vol. 50, No. 4, 527–533)
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Introduction
Breast cancer is the most frequent female cancer in
terms of diagnosis (in Europe, in 2006, 429,900 cases
were diagnosed which accounted for 13.5% of all can-
cer cases), and one of the three most frequent rea-
sons for mortality from among all types of cancer
(131,900 cases) [1]. In the United States in 2010, ap-
proximately 207,000 new cases of breast cancer were
diagnosed and around 40,000 died from the disease
[2]. Although the diagnostic process of breast cancer
has been improved, this disease poses a great health
problem, because of the lack of reliable molecular
prognostic factors. However, the development of mo-
lecular biology has made it possible to define new
potential prognostic factors which may have clinical
significance. One of these could be heat shock pro-
tein 27 (Hsp27).
Heat shock proteins (Hsps) are highly conserved
proteins of which the expression in the cell increases
in stress conditions [3]. They have many functional
activities such as control of new protein formation,
facilitation of transport through the cell’s membrane,
or repair of stress factor-induced damage [3, 4]. Hsp27
belongs to the family of small Hsps and is expressed
in the cytoplasm of a mammal’s cells such as myocar-
dial and skeletal muscle cells [5, 6]. It protects cells
from apoptotic factors like cytokines, cytostatic drugs,
and ionic radiation by increasing the activation of the
NF-kB signaling pathway and by influencing the cel-
lular inflammatory response [7, 8]. Increased level of
glutathione and modulation of microfilament stabili-
ty have been found to correlate with a high level of
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Hsp27 expression [9]. Hsp27 has been noted to be
overexpressed in breast, ovarian, esophageal, liver and
lung cancer [10]. It is significantly associated with es-
trogen receptor expression in endometrial and female
breast carcinoma [10]. High expression of Hsp27 has
been found to correlate with resistance to cisplatin,
doxorubicin and other anticancer drugs used in breast
cancer chemotherapy [11]. The expression of Hsp27
decreases the metastatic potential by increasing the
expression of E-cadherin and decreasing the expres-
sion of MCAM/MUC18 (MCAM, melanoma cell ad-
hesion molecule) in melanoma cells [12].
In this research, we determine the expression of
Hsp27 protein in fibrocystic breast changes (FC) and
human invasive ductal breast carcinoma (IDC) using
immunohistochemical methods with regards to the
patients’ clinicopathological data.
Material and methods
Patients. The study was performed on archival paraffin
blocks of 20 cases of FC and 101 cases of IDC from patients
treated in the Lower Silesian Oncology Center in Wroclaw
during the years 1999–2002. Most of the patients were treat-
ed surgically with radical mastectomy or conservative
quadrantectomy followed by axillary lymph node resection.
In cases of disease stage 3 and above, neoadjuvant therapy
was administered. All tissue specimens used in this study
were collected before the beginning of the treatment. The
clinical and pathological data were obtained from the ar-
chives of the Lower Silesian Oncology Center (Table 1).
Patients were followed for 52.77 (range 1–118) months.
Immunohistochemistry (IHC). Tissue samples were fixed
in 10% buffered formalin and embedded in paraffin. For
immunohistochemical staining, 4-µm-thick paraffin sections
were cut. Deparaffinization and antigen retrieval were per-
formed in Target Retrieval Solution, pH 9 (97°C, 20 min)
and PT Link platform (Dako, Glostrup, Denmark). Then
the sections were washed in TBS and stained (4°C, over-
night) with primary rabbit polyclonal antibody directed
against p-Hsp27 (sc-101700, Santa Cruz Biotechnology, Inc.,
Santa Cruz, CA, USA) and with primary antibody against
Ki-67 (MIB-1; 1:100; RT, 20 min; Dako) using the Autostain-
er Link 48 (Dako). Then the slides were washed in TBS and
visualization of the studied antibodies was performed using
the EnVision FLEX system (Dako) according to the manu-
facturer’s instructions. All slides were counterstained with
Mayer’s hematoxylin (Dako).
For all sections, a staining for estrogen receptor (ER),
progesterone receptor (PR) and human epidermal growth
factor receptor-2 (HER-2) was performed as previously
described [13]. Briefly, 4-µm-thick paraffin sections were
cut, dewaxed, gradually rehydrated and boiled in Antigen
Retrieval Solution (pH 6; Dako). The activity of endoge-
nous peroxidase was blocked with 3% H2O2. Slides were
then incubated overnight at 4°C with primary antibodies
(clone 1D5 at 1:100 dilution for ER, clone PgR 636 at 1:100
dilution for PR; both Dako). Following incubation with sec-
ondary biotinylated antibodies (Biotinylated Link), reactions
with the streptavidin-biotinylated peroxidase complex
(LSAB+ System-HRP; Dako) were performed. The per-
oxidase substrate of 3,3'-diaminobenzidine (DAB+ Chro-
mogen) was used as a chromogen. All the sections were
counterstained with hematoxylin. Expression of HER-2 was
examined using a HercepTest™ (Dako) kit, according to the
procedure recommended by the manufacturer.
Table 1. Patient and tumor characteristics
Mean age in years (range) 57 ± 11 (35–83)
Parameters Number %
Age
£ 50 31 30.09
> 50 70 69.91
Menopausal status
Pre 68 67.33
Post 33 32.67
Grade of malignancy
G1 9 8.91
G2 52 51.49
G3 40 39.60
pT
T1 55 54.46
T2 35 34.65
T3 8 7.92
T4 3 2.97
pN
pN0 52 51.49
pN1, pN2, pN3 46 45.54
pNx 3 2.97
ER
Positive 81 80.20
Negative 20 19.80
PR
Positive 70 69.03
Negative 31 31.97
HER-2 by IHC
Positive 16 15.84
Negative 85 84.16
Ki-67
< 25% 72 71.29
≥ 25% 29 28.71
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Histopathological examination and analysis of IHC. H&E sec-
tions were evaluated by two independent pathologists (WA, DP)
to confirm the diagnosis and assess the grade of malignancy and
presence of necrosis. Sections were regarded as positive when
the extent of the necrotic area was greater than 10%.
All immunostainings were evaluated by two pathologists
using a BX-41 light microscope (Olympus, Tokyo, Japan).
For the Hsp27 evaluation, immunoreactive scale of Rem-
mele was applied [14] (Table 2). The Ki-67 antigen was eval-
uated according to tumor cell positivity and encoded as fol-
lows: 0 (0% cells stained), 1 (1–10% cells stained), 2 (11–
–25% cells stained), 3 (26–50% cells stained), and 4 (51–
–100% cells stained).
PR and ER analysis was evaluated according to the per-
centage of positive cancer cells in whole tissue sections on
a four-grade scale as follows: 0% — 0, 1–10% — 1, 11–50%
— 2; and 51–100% — 3. Sections scoring 1 and above were
regarded as positive. HER-2 sections scoring 3 were regard-
ed as positive [15].
Statistical analysis. Statistical analysis was performed by
Prism 5.0 (GraphPad, CA, USA). Correlations between ex-
pression of Hsp27 and Ki-67 were analyzed by Spearman’s
correlation test. The correlations between expression of
Hsp27 and clinicopathological parameters were analyzed
by: Kruskal-Wallis, Mann-Whitney tests (tumor grade) and
Fischer exact test. The Mantel Cox test was used to com-
pare the differences in patient survival. Results were con-
sidered statistically significant with p < 0.05 in all analyses.
Results
Hsp27 cytoplasmic expression was noted in breast
duct cells of FC (2.50 ± 0.76) and in myofibroblasts
of breast acini and vessels of breast stroma (Figure
1A). Hsp27 expression was noted in 92 (92.1%) ex-
amined cases of IDC (4.97 ± 3.10; Figures 1B–D). In
some cases, additional expression was observed in
cancer cell nuclei. Significant difference in Hsp27
Figure 1. Hsp27 expression in breast duct cells (A) and IDC cases of G1 (B), G2 (C) and G3 (D). Magnification × 200
Table 2. Remmele scale: percentage of positive cells (A) and the intensity of color reaction (B). The final score represents
the product of these parameters (A×B)
A B
0 pts — no cells with positive reaction 0 pts — no staining
1 pt — to 10% cells with positive reaction 1 pt — low intensity of staining
2 pts — 11–50% cells with positive reaction 2 pts — moderate intensity of staining
3 pts — 51–80% cells with positive reaction 3 pts — intense staining
4 pts — > 80% cells with positive reaction
100 mm
100 mm100 mm
100 mm
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expression was observed between FC and IDC (Fig-
ure 2A). Moreover, when this relationship was ana-
lyzed regarding the grade of malignancy, a positive
trend of Hsp27 expression was observed in IDC, al-
though it was not significant (Figure 2B). Almost sig-
nificant higher expression of Hsp27 was noted in G3
cancers compared to cases of G1 (p = 0.0524).
Hsp27 expression was associated with HER-2 po-
sitivity (p = 0.0153), and cases which were HER-2
positive tended to have higher levels of Hsp27
(p = 0.072; Table 3, Figure 3). Our study revealed no
correlation of Hsp27 expression with tumor cell pro-
liferation measured by the expression of Ki-67 anti-
gen. Univariate analysis showed no impact of Hsp27
on patients’ clinical outcome and event free survival.
Discussion
The expression of Hsp27 in malignant cells has been
observed in many studies. To date, its expression has
been detected in breast, endometrial, ovarian, lung
cancer, melanoma and others [10, 16–24]. In ovarian,
prostate and gastric cancer, a high level of Hsp27 ex-
pression was associated with a poor clinical outcome
[10]. Some studies have shown that Hsp27 is not
a useful prognostic factor, and therefore on the basis
of results obtained by others we analyzed its expres-
sion in a different group of patients with IDC [25].
Our study showed significant differences between
the expression of Hsp27 in the group of IDC cases
compared to FC cases. Although our study did not
show any statistical difference between Hsp27 expres-
sion in cases of FC and G1 cases of IDC, significantly
higher Hsp27 expression was noted in FC in relation
to G2 and G3 IDC cases. Hsp27 expression was al-
most significantly higher in G3 than in G1 cases. There
was also a trend of higher expression of Hsp27 in G2
compared to G1. This indicates that Hsp27 could in-
fluence IDC malignancy. However, our results did not
reveal any positive correlation between level of Hsp-
27 and Ki-67.
These results conflict with recently published data
which demonstrated that Hsp-27 expression was in-
versely correlated with the grade of malignancy of
invasive ductal breast cancer [26]. In astrocytoma and
hepatocellular cancer, Hsp27 expression was positive-
ly correlated with grade of malignancy [27–29]. How-
ever, no significant correlation between grade of ma-
lignancy and level of Hsp27 expression in ovarian can-
cer, squamous cell carcinoma of the tongue and
esophagus, bladder carcinoma or gastric cancer was
observed [30–32]. That suggests that the expression
of Hsp27 has a heterogeneous character and is spe-
cific for the type of tumor; the role of this protein in
carcinogenesis remains unclear.
Hsp27, which is also known as a cytoplasmic es-
trogen receptor associated protein (p29), selectively
binds GTP and to a lesser extent ATP and plays
a role in the estrogen response intracellular pathways
[33, 34]. Our study did not show any correlation be-
tween Hsp27 expression and the expression of ER
and PR. Our data is in agreement with similar results
obtained by others [26, 35–38], although the study by
Ciocca et al. described a positive correlation between
Hsp27 and ER [16]. This discrepancy needs further
investigation.
We have also shown that Hsp27 expression corre-
lates with HER-2 expression. Similar results were
Figure 2. Statistical analysis revealed significantly higher Hsp27 expression in IDC compared to breast duct cells of FC
(p < 0.0001) (A). When the relationship between its expression in mastopathies and in different malignancy grades was
analyzed, significantly higher Hsp27 expression was observed in G2 (p = 0.0047) and G3 cases (p < 0.0001) (B).
**p < 0.005, ***p < 0.0001
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demonstrated by Liebhardt et al. [39]. The study by
Meng et al. revealed that heat-shock transcription
factor HSF1 has an important role in cellular trans-
formation induced by HER-2 [40]. Cells with knock-
down of HSF1 presented lower foci formation and
reduced tumor growth when xenografted to mice. In
HER-2 positive breast cancer cell lines, loss of HSF1
expression was associated with increase of p21 and
decrease of cells survival, Hsp27 and Hsp72 expres-
sion [40, 41]. The results obtained in this study are in
agreement with the results obtained by Meng et al. in
their research. Kang et al. demonstrated in breast
cancer cells that the high expression of Hsp27 increas-
es HER-2 stability, by the formation of a HER-2-
-Hsp27 complex therefore reducing the susceptibility
to Herceptin treatment [41]. Cardoso et al. focused
their work on the description of various markers in
breast cancer and metastatic lymph nodes, including
HER-2 and Hsp27, but the authors did not analyze
the relationship between those two proteins [42].
Their results showed that Hsp27 was present in 44%
of the examined primary tumors (compared to our
92.1%). These differences might be the result of us-
ing a different cut-off for the definition of positivity
[42]. Moreover, in our study, all cases of diffuse cys-
tic mastopathies were characterized by the expression
of Hsp27.
Our results showed that Hsp27 may be involved
in the early steps of carcinogenesis. Although our re-
sults did not demonstrate any correlation between
Hsp27 expression and clinico-pathological factors, the
correlation of Hsp27 and HER-2 may be an interest-
ing point of research in determining carcinogenesis
Table 3. Correlations between Hsp27 expression and clinico-pathological characteristics of studied patients. Significant
p values are given in bold
Characteristics Number (%) Hsp27 expression (number (%) p
IRS 0–4 IRS 6–12
Age
£ 50 31 (30.09) 13 (41.93) 18 (58.07) 0.1358
> 50 70 (69.91) 41 (58.6) 29 (41.4)
Menopausal status
Pre 33 (32.67) 13 (39.39) 20 (60.61) 0.0587
Post 68 (67.33) 41 (60.29) 27 (39.71)
Tumor size
pT1 55 (54.45) 29 (52.72) 26 (47.28) 0.8437
pT2-4 46 (45.55) 25 (54.35) 21 (45.65)
Lymph nodes
N0 52 (51.49) 30 (57.69) 22 (42.31) 0.4178
N1–3 46 (45.54) 22 (47.82) 24 (52.18)
ER
Positive 81 (80.20) 43 (53.08) 38 (46.92) 1.0000
Negative 20 (19.80) 11 (55.00) 9 (45.00)
PR
Positive 70 (69.03) 38 (54.28) 32 (45.72) 0.8317
Negative 31 (31.97) 16 (51.61) 15 (48.39)
HER-2
Positive 16 (15.84) 4 (25.00) 12 (75.00) 0.0153
Negative 85 (84.16) 50 (58.82) 35 (41.18)
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Figure 3. Intensity of Hsp27 expression in HER-2 negative
and positive cases of IDC
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and progression of IDC. Moreover, a significantly
higher Hsp27 expression in less differentiated cases
of IDC may be indicative of its role in the early steps
of carcinogenesis.
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